Tag Archives: Leah R. Cann

Constellation Pharmaceuticals Inc (CNST) Receives a New Rating from Oppenheimer

Constellation Pharmaceuticals Inc (NASDAQ: CNST) received a Buy rating and a $21 price target from Oppenheimer analyst Leah R. Cann today. The company’s shares closed on Friday at $9.85. Cann observed: “We are initiating coverage of Outperform rating and a

Oppenheimer Sticks to Their Buy Rating for Verastem (VSTM)

Oppenheimer analyst Leah R. Cann maintained a Buy rating on Verastem (NASDAQ: VSTM) yesterday and set a price target of $16. The company’s shares closed yesterday at $7.79. Cann said: “Verastem’s loss per share of $0.30 was in line with

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Clovis Oncology (NASDAQ: CLVS), ObsEva SA (NASDAQ: OBSV) and Strongbridge Biopharma Plc (NASDAQ: SBBP)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Clovis Oncology (NASDAQ:CLVS), ObsEva SA (NASDAQ:OBSV) and Strongbridge Biopharma Plc (NASDAQ:SBBP). Clovis Oncology (CLVS) Oppenheimer analyst Leah R. Cann initiated coverage with a Hold rating

Analysts Offer Insights on Healthcare Companies: Syros Pharmaceuticals (NASDAQ: SYRS), Melinta Therapeutics Inc (NASDAQ: MLNT) and Vericel Corp (NASDAQ: VCEL)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Syros Pharmaceuticals (NASDAQ:SYRS), Melinta Therapeutics Inc (NASDAQ:MLNT) and Vericel Corp (NASDAQ:VCEL) with bullish sentiments. Syros Pharmaceuticals (SYRS) Oppenheimer analyst Leah R. Cann

Oppenheimer Maintains a Buy Rating on Neon Therapeutics Inc (NTGN)

In a report released yesterday, Leah R. Cann from Oppenheimer maintained a Buy rating on Neon Therapeutics Inc (NASDAQ: NTGN), with a price target of $20. The company’s shares closed yesterday at $12.16. Cann said: “Loss per share was $7.84

Analysts Are Bullish on These Healthcare Stocks: Kura Oncology (KURA), Editas Medicine Inc (EDIT)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Kura Oncology (NASDAQ:KURA) and Editas Medicine Inc (NASDAQ:EDIT) with bullish sentiments. Kura Oncology (KURA) Oppenheimer analyst Leah R. Cann maintained a Buy